Last updated: November 2, 2026
Human Albumin Grifols is a plasma-derived biologic used for volume expansion, hypoalbuminemia, cirrhosis-related complications, burns, surgery, and other hospital indications. Grifols does not publicly report revenue for Human Albumin Grifols as a standalone product, so its financial trajectory must be assessed through Grifols’ Biopharma business, plasma collection network, albumin market conditions, and broader plasma-derived product results.
The product’s commercial position is supported less by patent exclusivity than by manufacturing scale, donor-plasma access, regulatory approvals, hospital contracts, and supply reliability. Generic-style substitution is limited because albumin is a biologic manufactured from human plasma, although competing plasma-derived albumin products create meaningful price and tender pressure.
What is Human Albumin Grifols?
Human Albumin Grifols is a sterile, plasma-derived human albumin product supplied in different concentrations and presentations, including 5% and concentrated formulations such as 20% or 25%, depending on jurisdiction and product registration. Grifols markets albumin products through its plasma-derived medicines portfolio.
Albumin is a major plasma protein. Commercial production requires:
- Collection and testing of human plasma.
- Plasma pooling and fractionation.
- Purification and viral inactivation or removal.
- Sterile filling and quality-control release.
- Distribution through hospital, government, and specialty-care channels.
The product is used in acute-care settings rather than primarily through retail pharmacies. Demand is therefore tied to hospital utilization, critical-care protocols, cirrhosis treatment, surgery, transplantation, burns, and national procurement programs.
What indications and formulations are protected by Human Albumin Grifols?
The primary commercial formulations are differentiated by albumin concentration, container size, excipients, labeling, and route of administration. The 5% formulation is generally used for volume replacement, while 20% and 25% formulations are used when concentrated albumin administration is clinically appropriate.
| Product characteristic |
Commercial relevance |
| 5% albumin |
Volume expansion and replacement therapy |
| 20% or 25% albumin |
Concentrated therapy for selected hospital indications |
| Intravenous administration |
Requires hospital or controlled clinical use |
| Plasma-derived source |
Creates supply, testing, and manufacturing barriers |
| Multiple vial or bottle sizes |
Supports hospital formulary and procurement requirements |
The central competitive asset is manufacturing consistency. Albumin products must meet strict standards for purity, sterility, viral safety, stability, and protein concentration. Formulation differences can affect hospital purchasing, but they generally do not create durable patent barriers comparable with a novel small molecule.
What is the patent status of Human Albumin Grifols?
Human Albumin Grifols does not appear to depend on an active, product-specific patent moat in the United States. The relevant protection is primarily regulatory, manufacturing, quality-system, and supply-chain protection.
| Protection category |
Position for Human Albumin Grifols |
| Core composition patent |
No material active composition patent is publicly central to the product |
| Formulation patents |
Limited commercial importance; concentration and excipient differences are generally not strong standalone barriers |
| Method-of-use patents |
Not the principal source of market exclusivity |
| Manufacturing know-how |
Important and difficult to replicate at scale |
| Plasma supply network |
Major practical barrier to entry |
| FDA biologic approval |
Required for lawful U.S. marketing |
| Orange Book listing |
Not the principal U.S. patent framework for this biologic |
| Purple Book relevance |
Biologic reference-product records and biosimilar status are more relevant |
The FDA Orange Book is principally associated with approved drug products and patent certifications for abbreviated new drug applications. Albumin is a biologic product regulated through a biologics license framework, making the Purple Book and biologics licensing process more relevant than a conventional Orange Book Paragraph IV analysis. [1,2]
When does Human Albumin Grifols lose exclusivity?
Human Albumin Grifols does not have a single, clearly disclosed patent-expiration date that determines generic entry. The product’s commercial exclusivity is based on its biologic license, manufacturing authorization, quality systems, plasma access, and customer relationships.
A traditional small-molecule generic cannot enter simply by certifying against an Orange Book patent. A competitor would need its own approved albumin product or another legally available regulatory pathway. A biosimilar pathway could theoretically apply to a reference biologic, but albumin has not developed the same biosimilar competition model seen in monoclonal antibodies, insulin, or filgrastim.
The main practical entry risks are therefore:
- New plasma-derived albumin products from established fractionators.
- Domestic manufacturers in China and other large markets.
- Hospital tender losses.
- Price controls or reimbursement changes.
- Supply interruptions that favor competitors with available inventory.
- Manufacturing or regulatory findings affecting a specific facility.
Are there Paragraph IV challenges to Human Albumin Grifols?
No material public Paragraph IV challenge is central to Human Albumin Grifols’ commercial outlook. Paragraph IV litigation is designed for ANDA-based generic drug applications. Albumin competition is more likely to arise through separate biologic approvals, plasma-derived product approvals, procurement competition, or biosimilar-type regulatory filings.
The absence of a prominent Paragraph IV case does not eliminate competitive risk. It means that the relevant risk is operational and regulatory rather than a conventional patent cliff.
Are there biosimilars to Human Albumin Grifols?
There is no established U.S. biosimilar market for human albumin comparable with the markets for adalimumab, trastuzumab, rituximab, or pegfilgrastim. The FDA’s Purple Book provides the relevant reference point for biosimilar and interchangeable biologic listings. [2]
Albumin is difficult to treat as a simple copy product because commercial products depend on:
- Large-scale human plasma pools.
- Donor screening and infectious-disease testing.
- Fractionation yield.
- Viral inactivation and removal.
- Process validation.
- Batch consistency.
- Cold-chain and hospital distribution.
A future competing biologic could still pressure pricing, particularly in markets where albumin is procured through tenders and clinical interchangeability is accepted by hospitals.
What is the FDA regulatory status of Human Albumin Grifols?
Grifols’ albumin products are regulated as biologic products in the United States. Product labeling identifies the approved concentrations, indications, contraindications, warnings, dosage information, and manufacturing entity. The FDA-approved label for Grifols albumin products is the controlling source for U.S. use. [3]
Albumin carries regulatory risks that are distinct from ordinary sterile injectables. FDA scrutiny can focus on:
- Plasma donor eligibility.
- Viral safety.
- Manufacturing deviations.
- Facility inspection findings.
- Sterility assurance.
- Product complaints.
- Labeling and pharmacovigilance.
- Chain-of-custody controls.
The regulatory license is durable only while the manufacturer maintains compliance and supply continuity.
How large is the human albumin market?
Human albumin is one of the largest plasma-derived protein markets, although market estimates vary because reporting can include different concentrations, geographies, hospital channels, and related plasma proteins.
Demand is strongest in:
- China, where albumin has historically held high clinical and consumer recognition.
- The United States, where hospital use is concentrated in critical care and specialty indications.
- Europe, where national reimbursement and hospital procurement systems influence use.
- Emerging markets, where access depends on public tenders and imported supply.
Albumin demand has several structural supports:
- Aging populations.
- Rising prevalence of cirrhosis and liver disease.
- Growth in intensive-care capacity.
- Greater use in transplantation and complex surgery.
- Expansion of plasma-derived medicine access in developing markets.
The main demand constraint is clinical-utilization scrutiny. Hospitals and payers increasingly evaluate whether albumin improves outcomes over lower-cost alternatives such as crystalloids or other volume expanders in particular settings.
What drives the market dynamics for Human Albumin Grifols?
Plasma supply and fractionation economics
Albumin is produced from human plasma and is economically linked to the broader plasma-fractionation system. Grifols’ plasma centers, testing infrastructure, fractionation plants, and distribution network support albumin availability. The same system also supplies immunoglobulins and other plasma-derived products.
Plasma collection growth can support albumin volume, but the economics are not determined by albumin alone. Immunoglobulin products generally carry greater pricing power and have been a central growth driver for large fractionators. Albumin may be produced as part of the overall fractionation portfolio even when its standalone margin is lower.
China pricing and procurement
China is strategically important for albumin demand but also exposes manufacturers to tender pricing, domestic competition, regulatory requirements, and reimbursement changes. Grifols has historically identified China as an important market for plasma-derived products. Pricing pressure in China can affect the realized value of albumin even when volume remains strong.
Hospital budget pressure
Albumin is more expensive than many crystalloid alternatives. Hospital protocols, pharmacy committees, and payer policies can restrict use in indications where clinical benefit is viewed as uncertain. This limits the ability of manufacturers to raise prices solely on the basis of biological complexity.
Supply reliability
Shortages can shift demand among suppliers. A manufacturer with reliable plasma collection and finished-product inventory can gain share during competitor disruptions. Conversely, a manufacturing deviation or inspection issue can produce rapid hospital substitution.
What is the financial trajectory of Human Albumin Grifols?
Grifols does not disclose Human Albumin Grifols revenue, gross margin, or operating profit as a separate line item. Product-level financial exposure is therefore not quantifiable from public company reporting. The relevant proxy is Grifols’ total revenue and plasma-derived medicines performance.
| Fiscal year |
Grifols consolidated revenue |
| 2022 |
Approximately €6.1 billion |
| 2023 |
Approximately €6.6 billion |
| 2024 |
Approximately €7.2 billion |
Grifols reported approximately €6.592 billion of revenue in 2023 and approximately €7.212 billion in 2024. [4,5] The increase reflected volume growth, pricing, foreign-exchange effects, plasma collection expansion, and portfolio performance across plasma-derived products. It should not be attributed specifically to Human Albumin Grifols.
The albumin business has a mixed financial profile:
- Revenue is supported by recurring hospital demand.
- Volume benefits from expanded plasma collection and manufacturing capacity.
- Price growth is constrained by tenders and clinical substitution.
- Margins depend on plasma procurement cost, fractionation yield, plant utilization, and product mix.
- Albumin may absorb or share costs across the broader plasma portfolio.
- Immunoglobulin demand can provide stronger growth and profitability than albumin.
Grifols’ high leverage and refinancing requirements also affect the commercial interpretation of albumin. Stable albumin cash flow has value because it supports portfolio breadth, but albumin alone is unlikely to resolve the company’s balance-sheet exposure. [4,5]
Which companies compete with Human Albumin Grifols?
The principal competitors are other plasma-derived albumin manufacturers.
| Company |
Competitive position |
| CSL Behring |
Large global plasma collector and albumin supplier |
| Takeda |
Plasma-derived portfolio with international hospital presence |
| Octapharma |
Human plasma-derived therapies, including albumin in selected markets |
| Kedrion |
Albumin and other plasma-derived products |
| LFB |
Plasma-derived medicines, particularly in Europe and selected markets |
| Chinese manufacturers |
Increasing relevance in China and regional procurement |
Competition is market-specific. A supplier may be strong in the United States but less competitive in China, or strong in European tenders but weak in private hospital channels.
What patent litigation and settlement risks affect the product?
No major public patent litigation or Paragraph IV settlement appears to define the Human Albumin Grifols market. The more material legal and regulatory risks involve:
- Product liability.
- Plasma donor and infectious-disease claims.
- Manufacturing compliance.
- Facility inspections.
- Contract disputes.
- Government procurement.
- Product recalls or supply interruptions.
- Antitrust or pricing scrutiny in concentrated plasma markets.
The absence of patent litigation reduces cliff risk but does not eliminate legal exposure. A regulatory action affecting a fractionation facility could have a larger commercial effect than a conventional patent dispute.
How strong is the patent estate for Human Albumin Grifols?
The patent estate is weak as a standalone exclusivity asset and strong as part of an integrated manufacturing platform. The product’s defensibility comes from the combined difficulty of replicating:
- Global plasma collection.
- Donor recruitment and retention.
- Testing laboratories.
- Fractionation scale.
- Viral-safety validation.
- Regulatory history.
- Hospital distribution.
- Supply contracts.
This is a manufacturing and network moat rather than a traditional patent moat. A new entrant would need to duplicate the full biologics infrastructure, not merely design around a claim.
What generic launch scenarios exist for Human Albumin Grifols?
The most credible competitive scenarios are:
- Established fractionator expansion. A CSL Behring, Takeda, Octapharma, or Kedrion product gains hospital share through supply or pricing.
- Chinese domestic substitution. Local producers take volume in China through procurement advantages.
- Tender-driven price erosion. Grifols retains volume but accepts lower prices.
- Supply disruption. A Grifols facility or plasma network issue causes temporary share loss.
- New regulatory entrants. A separately approved plasma-derived albumin product enters selected markets.
A sudden U.S. generic cliff is less likely than gradual regional erosion caused by procurement, pricing, or supply events.
What licensing deals and partnerships affect Human Albumin Grifols?
No major product-specific licensing deal is publicly central to Human Albumin Grifols’ commercial profile. Grifols’ strategic position is driven primarily by ownership and operation of plasma centers, fractionation capacity, manufacturing sites, and distribution infrastructure.
The company’s acquisition of Biotest expanded its plasma-derived medicines platform and geographic reach, although Biotest is not a Human Albumin Grifols licensing transaction. [6] The deal increased the strategic importance of plasma supply, manufacturing utilization, and portfolio integration.
Key Takeaways
- Human Albumin Grifols is a plasma-derived biologic with no clear product-specific patent cliff.
- Grifols does not disclose standalone albumin revenue, so company-level revenue is only a proxy.
- Grifols revenue increased from about €6.1 billion in 2022 to €7.2 billion in 2024.
- The main barriers are plasma access, fractionation capacity, regulatory compliance, and hospital supply reliability.
- Paragraph IV litigation is not the principal competitive threat.
- The U.S. market has no established biosimilar albumin competition comparable with major monoclonal antibody markets.
- China, hospital tenders, and clinical-utilization controls are the main pricing variables.
- Albumin provides recurring revenue but generally has less pricing power than immunoglobulin products.
- Competitor entry is more likely through separately approved plasma-derived products than through a conventional generic launch.
FAQs About Human Albumin Grifols
Is Human Albumin Grifols a biosimilar?
No established U.S. biosimilar market for Human Albumin Grifols exists. Competing products would generally require their own biologic or plasma-derived product approvals.
Does Human Albumin Grifols have an Orange Book patent?
The product is not primarily protected through the conventional Orange Book patent-certification system. Its commercial protection comes from biologic approval, manufacturing controls, plasma supply, and regulatory know-how.
Who manufactures competing human albumin products?
Major competitors include CSL Behring, Takeda, Octapharma, Kedrion, LFB, and Chinese plasma-derived medicine manufacturers.
Is albumin more profitable than immunoglobulin for Grifols?
Generally, immunoglobulin has stronger pricing power and strategic importance. Albumin remains commercially valuable because it is a recurring product within the plasma-fractionation portfolio.
What is the biggest risk to Human Albumin Grifols revenue?
The largest risks are tender-price erosion, hospital utilization controls, plasma supply constraints, manufacturing disruptions, and competition from other approved plasma-derived albumin products.
References
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
-
U.S. Food and Drug Administration. (n.d.). Human albumin Grifols prescribing information. FDA-approved product labeling.
-
Grifols, S.A. (2024). Annual report 2023. https://www.grifols.com/
-
Grifols, S.A. (2025). Annual report 2024. https://www.grifols.com/
-
Grifols, S.A. (2022). Grifols completes acquisition of Biotest. https://www.grifols.com/
